Drug-Coated Balloons: How Should We Incorporate Into Our Practice in Treating Superficial Femoral Artery Lesions?

被引：4

作者：

Zeller T. ^{[1
]}

Rastan A. ^{[1
]}

Macharzina R. ^{[1
]}

Beschorner U. ^{[1
]}

Noory E. ^{[1
]}

机构：

[1] Universitäts-Herzzentrum Freiburg – Bad Krozingen, Südring 15, Bad Krozingen

来源：

Current Treatment Options in Cardiovascular Medicine | 2015年 / 17卷 / 5期

关键词：

Angioplasty; Drug eluting balloon; Drug-coated balloon; Paclitaxel; Peripheral artery disease; Superficial femoral artery;

D O I：

10.1007/s11936-015-0380-3

中图分类号：

学科分类号：

摘要：

Drug-coated balloons (DCBs) provide a novel method to locally deliver paclitaxel into the arterial wall without the need of a chronically implanted delivery system. Following the first positive pilot studies, two large pivotal trials have confirmed superiority of DCBs over plain old balloon angioplasty (POBA) in the treatment of TASC II A and B femoro-popliteal lesions. Even for more complex femoro-popliteal lesions such as long lesions and in-stent restenosis, single-center studies and small randomized studies have shown promising mid-term technical and clinical results. This review article summarizes the current knowledge about DCBs in femoro-popliteal interventions, supplements published guidelines with evidence-based recommendations, and discusses still unresolved needs. © 2015, Springer Science+Business Media New York.

引用

页数：11

共 27 条

[1]

Norgren L., Hiatt W.R., Dormandy J.A., Et al., Inter-society consensus for the management of peripheral arterial disease, Int Angiol, 26, pp. 81-157, (2007)

[2]

Beschorner U., Sixt S., Schwarzwalder U., Et al., Recanalization of chronic occlusions of the superficial femoral artery using the outback™ re-entry catheter: a single centre experience, Catheter Cardiovasc Interv, 74, pp. 934-938, (2009)

[3]

Johnston K.W., Femoral and popliteal arteries: reanalysis of results of balloon angioplasty, Radiology, 183, pp. 767-771, (1992)

[4]

Schillinger M., Sabeti S., Loewe C., Et al., Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery, N Engl J Med, 354, pp. 1879-1888, (2006)

[5]

Tepe G., Zeller T., Albrecht T., Et al., Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg, N Engl J Med, 358, pp. 689-699, (2008)

[6]

Werk M., Langner S., Reinkensmeier B., Et al., Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial, Circulation, 118, pp. 1358-1365, (2008)

[7]

Werk M., Albrecht T., Meyer D.R., Et al., Paclitaxel-coated balloons reduce restenosis after femoro-popliteal angioplasty: evidence from the randomized PACIFIER trial, Circ Cardiovasc Interv, 5, pp. 831-840, (2012)

[8]

Scheinert D., Duda S., Zeller T., Et al., The LEVANT I (Lutonix Paclitaxel-Coated Balloon for the Prevention of Femoropopliteal Restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty, JACC Cardiovasc Interv, 7, pp. 10-19, (2014)

[9]

Micari A., Cioppa A., Vadala G., Castriota F., Liso A., Marchese A., Et al., Clinical evaluation of a paclitaxel-eluting balloon for treatment of femoropopliteal arterial disease: 12-month results from a multicenter Italian registry, JACC Cardiovasc Interv, 5, pp. 331-338, (2012)

[10]

Rocha-Singh K.J., Zeller T., Jaff M.R., Peripheral arterial calcification: prevalence, detection and clinical implications, Catheter Cardiovasc Interv, 83, pp. 212-220, (2014)

← 1 2 3 →